EverGlade's Stephen Richardson and Laura (Powell) Grace Elected to BioMaP and MCDC Leadership Roles
EverGlade's Stephen Richardson and Laura (Powell) Grace Elected to BioMaP and MCDC Leadership Roles
PR Newswire
HOUSTON, Oct. 16, 2026
Two consortium leadership roles position EverGlade to help strengthen industry-government collaboration
HOUSTON, Oct. 16, 2026 /PRNewswire/ -- EverGlade, a federal funding advisory firm serving life sciences and technology innovators, announced that Stephen Richardson, Head of Strategic Partnerships, and Laura (Powell) Grace, PhD, Director, have been elected to leadership positions with two consortia supporting national health security.

Mr. Richardson will serve as Chair for Voice of Membership on the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) Executive Steering Committee. Mrs. Grace will serve as a Small Business Representative on the Medical CBRN Defense Consortium (MCDC) Executive Committee. Both roles provide opportunities to bring industry experience and member priorities into dialogue with consortium leadership and government partners.
Strengthening the Voice of Membership at BioMaP
BioMaP supports the nation's biopharmaceutical manufacturing preparedness, including domestic supply chain resilience and collaboration between industry and government. Mr. Richardson will focus on gathering member feedback to help inform consortium priorities and improve the value of participation.
"I appreciate the members' confidence in me," said Mr. Richardson. "BioMaP's strength is in its members and the expertise they bring. My focus is to listen to their concerns, improve how they connect with leadership and the government, and make sure their perspectives help guide how BioMaP plans and moves forward. That's how we strengthen the nation's biomanufacturing preparedness and response."
Representing Small Businesses at MCDC
MCDC brings together industry, academia, and government to advance medical countermeasures against chemical, biological, radiological, and nuclear threats. Mrs. Grace will bring firsthand insight into the priorities and practical challenges of companies pursuing and executing MCDC-funded programs.
"Small businesses bring unique capabilities to medical countermeasure development," said Mrs. Grace. "Working with companies pursuing and managing MCDC awards gives me a firsthand view of where dialogue between government and industry can be more productive. My priority is to bring that perspective into committee discussions and help keep promising programs moving forward."
The appointments reflect EverGlade's mission of connecting innovators with federal partners and supporting programs from pursuit through delivery.
"We are proud to have our leaders serve in these critical roles," shared Giacomo Apadula, CEO. "Stephen and Laura will help shape consortium priorities, strengthen industry-government collaboration, and improve program outcomes for members and awardees."
About EverGlade
EverGlade partners with life sciences and technology innovators navigating the federal funding ecosystem. The firm supports the full funding lifecycle from technical strategy and proposals to negotiations and post-award execution.
Contact:
info@everglade.com

SOURCE EverGlade Consulting
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

7 Undervalued Stocks That Crushed Earnings

This Newly Undervalued Stock Has Plenty of Growth Ahead

Are These Riskier Bond ETFs Worth the Higher Yields?

